Page last updated: 2024-10-27

fluspirilene and Diabetes Mellitus, Type 2

fluspirilene has been researched along with Diabetes Mellitus, Type 2 in 1 studies

Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Tabatabaei Dakhili, SA1
Greenwell, AA1
Yang, K1
Abou Farraj, R1
Saed, CT1
Gopal, K1
Chan, JSF1
Chahade, JJ1
Eaton, F1
Lee, C1
Velázquez-Martínez, CA1
Crawford, PA1
Glover, JNM1
Al Batran, R1
Ussher, JR1

Other Studies

1 other study available for fluspirilene and Diabetes Mellitus, Type 2

ArticleYear
The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase.
    Diabetes, 2023, 01-01, Volume: 72, Issue:1

    Topics: Animals; Antipsychotic Agents; Coenzyme A-Transferases; Diabetes Mellitus, Type 2; Dopamine; Fluspir

2023